Palliative Thoracic ImmunoRT
Study Description
“Palliative Thoracic ImmunoRT”
The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 Gy in 10 fractions.
Location
Methods
No pharmaceutical medication involved
Recruiting patients only
Radiation - Radiation combined with immunotherapy
The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 Gy in 10 fractions.
Additional Information
Official Study Title
Evaluation of Toxicities With Thoracic Radiotherapy and Immune Checkpoint Inhibition in Non-small Cell Lung Cancer
Clinical Trial ID
NCT03705806
ParticipAid ID
aQW7ld
